Effect of D2-dopamine receptor antagonist levosulpiride on diabetic cholecystoparesis: a double-blind crossover study

Aliment Pharmacol Ther. 1995 Apr;9(2):185-9. doi: 10.1111/j.1365-2036.1995.tb00369.x.

Abstract

Background: Abnormal gall-bladder motility has been reported in diabetics. The objective was to evaluate the effect of chronic D2-dopamine receptor inhibition on gall-bladder emptying in diabetic patients.

Methods: Under double-blind placebo-controlled conditions and according to a crossover design, patients were randomly assigned to receive either 4 weeks treatment with levosulpiride 25 mg t.d.s. or 4 weeks treatment with placebo, with an interval of 15 days. Twenty-three consecutive long-standing, insulin-treated diabetics with autonomic neuropathy were studied.

Measurements: At the beginning of the study and after levosulpiride or placebo treatment, gall-bladder emptying was measured ultrasonically by evaluating the gall-bladder volume in basal conditions and every 15 min for 90 min after the ingestion of a standard meal. Statistical analysis of the results was performed by means of analysis of variance.

Results: Levosulpiride treatment reduced the basal mean gall-bladder volume from 21.6 +/- 2.3 to 18.6 +/- 2.3 mL (P < 0.05). Furthermore, the residual gall-bladder volume (9.3 +/- 1.4 mL) was significantly reduced compared to the corresponding pre-treatment volume (14.6 +/- 1.5 mL (P < 0.05). In placebo-treated patients, no significant differences were observed in gall-bladder volumes before and after treatment.

Conclusion: These results show that chronic oral administration of the D2-dopamine antagonist levosulpiride has a significant effect on gall-bladder motility in diabetic patients.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Cross-Over Studies
  • Diabetes Complications*
  • Dopamine D2 Receptor Antagonists*
  • Female
  • Follow-Up Studies
  • Gallbladder Diseases / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Paralysis / drug therapy*
  • Sulpiride / analogs & derivatives*
  • Sulpiride / therapeutic use
  • Time Factors

Substances

  • Dopamine D2 Receptor Antagonists
  • Sulpiride
  • levosulpiride